Frequently Asked Questions

This study has completed enrollment. The participants who have received AST-OPC1 will continue to be followed and Asterias Biotherapeutics will provide periodic study results updates at www.AsteriasBiotherapeutics.com.

AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells. AST-OPC1 was previously tested in the world’s first human clinical trial of a stem cell derived product.

AST-OPC1 was previously tested in a clinical study of people completely paralyzed from the waist down.

The previous clinical study of AST-OPC1 was designed to evaluate the safety of a single low dose. No clinical benefit was expected or reported from that study.

Lab studies have shown the cells in AST-OPC1 promote partial repair of damaged spinal cord tissue and some improvement in the ability of some animals to move their back and/or front legs.

The SCiStar study for spinal cord injury is sponsored by Asterias Biotherapeutics, Inc., a leader in the emerging field of regenerative medicine. Asterias is focused on developing therapies to treat diseases or serious injuries in areas with high unmet medical needs or inadequate therapies.